SANOFI PASTEUR
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- Subsidiary
- Established
- 1990-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.sanofipasteur.com
Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry
Completed
- Conditions
- PregnancyInfluenza
- Interventions
- Biological: Quadrivalent Influenza Vaccine (QIV)
- First Posted Date
- 2013-09-18
- Last Posted Date
- 2020-02-12
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 244
- Registration Number
- NCT01945424
Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine
Phase 2
Completed
- Conditions
- Dengue FeverDengueDengue Hemorrhagic Fever
- Interventions
- Biological: CYD Dengue VaccineBiological: Japanese Encephalitis Vaccine
- First Posted Date
- 2013-09-17
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 90
- Registration Number
- NCT01943825
Study of the Tdap Combined Vaccine (ADACEL™) as a Booster Dose in Healthy Adults and Children in China
Phase 1
Completed
- Conditions
- PertussisDiphtheriaTetanus
- Interventions
- Biological: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap
- First Posted Date
- 2013-09-02
- Last Posted Date
- 2016-03-07
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 40
- Registration Number
- NCT01933776
Purified Vero Rabies Vaccine-Serum Free Compared to Human Diploid Cell Vaccine in a Pre-exposure Prophylaxis Regimen
Phase 2
Completed
- Conditions
- Rabies
- Interventions
- Biological: Purified Vero Rabies Vaccine Serum Free (VRVg)
- First Posted Date
- 2013-08-28
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 342
- Registration Number
- NCT01930357
Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea
Phase 3
Completed
- Conditions
- Japanese Encephalitis
- Interventions
- Biological: IMOJEV
- First Posted Date
- 2013-07-16
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 119
- Registration Number
- NCT01900444
- Locations
- 🇰🇷
Investigational Site 004, Gyeonggi-do, Korea, Republic of
🇰🇷Investigational Site 010, Gyeonggi-do, Korea, Republic of
🇰🇷Investigational Site 001, Seoul, Korea, Republic of
Study of a Candidate Clostridium Difficile Toxoid Vaccine in Healthy Adult Subjects Aged 40 to 75 Years in Japan
Phase 1
Completed
- Conditions
- Clostridium Difficile Infection
- Interventions
- Biological: 0.9% normal salineBiological: Clostridium difficile Toxoid Vaccine
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2018-07-18
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 102
- Registration Number
- NCT01896830
Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation
Phase 3
Completed
- Conditions
- Meningococcal InfectionMeningitis
- Interventions
- Biological: Meningococcal Diphtheria Toxoid Vaccine
- First Posted Date
- 2013-07-02
- Last Posted Date
- 2022-04-19
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 300
- Registration Number
- NCT01890759
Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection
Phase 3
Terminated
- Conditions
- Clostridium Difficile Infection
- Interventions
- Biological: C. difficile Toxoid Vaccine
- First Posted Date
- 2013-06-27
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 9302
- Registration Number
- NCT01887912
- Locations
- 🇺🇸
Investigational Site 020, Wilkes-Barre, Pennsylvania, United States
🇺🇸Investigational Site 180, Spartanburg, South Carolina, United States
🇺🇸Investigational Site 104, Mobile, Alabama, United States
Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen
Phase 2
Completed
- Conditions
- Rabies
- Interventions
- Biological: Purified Vero Rabies Vaccine (VRVg)
- First Posted Date
- 2013-06-13
- Last Posted Date
- 2014-12-03
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 342
- Registration Number
- NCT01877395
Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination
Phase 3
Completed
- Conditions
- Neisseria MeningitidisBacterial InfectionsVirus Diseases
- Interventions
- Biological: Hexavalent vaccineBiological: NeisVac-CBiological: RotaTeqBiological: Prevenar 13Biological: NimenrixBiological: M-M-RVAXPRO
- First Posted Date
- 2013-04-24
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Sanofi Pasteur, a Sanofi Company
- Target Recruit Count
- 350
- Registration Number
- NCT01839175
- Locations
- 🇫🇮
Sanofi Pasteur MSD Investigational Site 003, Espoo, Finland
🇫🇮Sanofi Pasteur MSD Investigational Site 001, Helsinki, Finland
🇫🇮Sanofi Pasteur MSD Investigational Site 010, Kokkola, Finland
© Copyright 2025. All Rights Reserved by MedPath